Combination treatment for FLT3-mutated acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares a new combination treatment to standard chemotherapy plus a targeted drug (called an FLT3 inhibitor) in people with AML that has a FLT3 mutation. The goal is to see if the new approach works better and helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 to 74 years old.
- You have been newly diagnosed with AML or a related condition (MDS/AML) — not certain subtypes like APL or CBF-AML.
- Your leukemia has a change in the FLT3 gene (FLT3-ITD or FLT3-TKD).
- You are able to receive intensive chemotherapy (strong treatment for leukemia).
- You are generally well enough that light or moderate activity is possible (ECOG 0-2).
- Your liver, kidneys, and heart are working well enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.